BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BNTX BioNTech SE

盘前交易 06-22 06:50:38 EDT

90.89

-1.33

-1.44%

盘前89.80

-1.09-1.20%

06:44 EDT

最高93.25	最低90.12	成交量93.96万
今开92.16	昨收92.22	日振幅3.39%
总市值229.95亿	流通市值95.43亿	总股本2.53亿
成交额8,551万	换手率0.89%	流通股本1.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BNTX","market":"US","secType":"STK","nameCN":"BioNTech SE","latestPrice":90.89,"timestamp":1781812800000,"preClose":92.22,"halted":0,"volume":939597,"hourTrading":{"tag":"盘前","latestPrice":89.8,"preClose":90.89,"latestTime":"06:44 EDT","volume":743,"amount":66790.47671,"timestamp":1782125081111,"change":-1.09,"changeRate":-0.011993,"amplitude":0.009462},"delay":0,"changeRate":-0.014422034265885907,"floatShares":105000000,"shares":252999999,"eps":-5.894595,"marketStatus":"盘前交易","change":-1.33,"latestTime":"06-22 06:50:38 EDT","open":92.16,"high":93.25,"low":90.12,"amount":85510900.15182,"amplitude":0.033941,"askPrice":89.85,"askSize":320,"bidPrice":89.38,"bidSize":320,"shortable":3,"etf":0,"ttmEps":-5.894595,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782135000000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1570680000000,"exchange":"NASDAQ","adjPreClose":90.89,"preHourTrading":{"tag":"盘前","latestPrice":89.8,"preClose":90.89,"latestTime":"06:44 EDT","volume":743,"amount":66790.47671,"timestamp":1782125081111,"change":-1.09,"changeRate":-0.011993,"amplitude":0.009462},"postHourTrading":{"tag":"盘后","latestPrice":91.65,"preClose":90.89,"latestTime":"19:50 EDT","volume":61619,"amount":5601545.875703,"timestamp":1781826610271,"change":0.76,"changeRate":0.008362,"amplitude":0.008362},"volumeRatio":0.693633280468881,"impliedVol":0.4329,"impliedVolPercentile":0.448},"requestUrl":"/m/hq/s/BNTX/tweets","defaultTab":"tweets","newsList":[{"id":"1156020992","title":"辉瑞与BioNTech新冠疫苗获授权，将为6个月至11岁儿童统一使用10微克剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1156020992","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156020992?lang=zh_cn&edition=full","pubTime":"2026-05-29 23:47","pubTimestamp":1780069665,"startTime":"0","endTime":"0","summary":"辉瑞公司与其合作伙伴BioNTech SE共同研发的新冠疫苗已获得授权，将面向6个月至11岁的所有儿童群体，统一采用10微克的剂量进行接种。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0122379950.USD","IE00BLSP4239.USD","SG9999011175.SGD","LU0289739699.SGD","BK4568","IE00B19Z3B42.SGD","LU1883839398.USD","BK4550","IE00BLSP4452.SGD","BK4581","BNTX","LU0306806265.USD","LU0321505439.SGD","BK4599","BK4548","SGXZ57979304.SGD","BK4534","LU0868494617.USD","LU1894683264.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","PFE","LU0170899867.USD","LU1057294990.SGD","BK4592","SG9999013999.USD","BK4007","LU0306807586.USD","IE0002270589.USD","BK4551","SG9999001176.SGD","IE00B3T34201.USD","LU0985481810.HKD","SG9999002232.USD","LU0225771236.USD","LU0225284248.USD","SG9999002224.SGD","SG9999001176.USD","IE00BBT3K403.USD","LU0234572021.USD","LU1066051498.USD","BK4533","LU1066053197.SGD","BK4535","LU0456855351.SGD","LU1894683348.USD","LU0321505868.SGD","BK4139","LU1023059063.AUD","BK4588","SG9999003800.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168798534","title":"辉瑞与BioNTech SE准备根据FDA建议并在获批后供应2026-2027新冠疫苗配方：简报文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1168798534","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168798534?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:19","pubTimestamp":1779970796,"startTime":"0","endTime":"0","summary":"辉瑞与BioNTech SE已准备就绪，将依据美国食品药品监督管理局的建议，并在获得正式批准后，供应针对2026至2027年度的更新版新冠疫苗配方。相关计划细节载于公司提交的简报文件之中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","LU0225284248.USD","SG9999002224.SGD","BK4548","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4139","BK4533","BK4599","LU1066053197.SGD","SG9999011175.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","LU0170899867.USD","LU0234572021.USD","LU0456855351.SGD","PFE","IE0002270589.USD","LU0868494617.USD","IE000M9KFDE8.USD","LU0058720904.USD","LU0306807586.USD","LU1057294990.SGD","BK4588","IE00BBT3K403.USD","BK4585","SG9999001176.SGD","LU0985481810.HKD","LU1023059063.AUD","LU0306806265.USD","BK4534","IE00BLSP4239.USD","LU1894683348.USD","BK4535","BK4592","BK4581","IE00B19Z3B42.SGD","BK4550","SG9999001176.USD","BK4007","SG9999002232.USD","SG9999013999.USD","BNTX","LU1066051498.USD","BK4551","LU0321505868.SGD","LU0289739699.SGD","LU1883839398.USD","LU0122379950.USD","LU1894683264.USD","BK4568","SG9999003800.SGD","LU0225771236.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115280811","title":"BioNTech首季营业亏损6.775亿欧元 营收逊于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1115280811","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115280811?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:08","pubTimestamp":1777979333,"startTime":"0","endTime":"0","summary":"生物技术公司BioNTech SE公布第一季度业绩，营业亏损达6.775亿欧元。当季营收为1.181亿欧元，大幅低于市场预估的1.67亿欧元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4139","BK4535","BK4585","BK4588","BK4568","BK4551","BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155749193","title":"异动解读 | BioNTech盘前大跌5.59%，因宣布关闭生产基地并转移疫苗生产","url":"https://stock-news.laohu8.com/highlight/detail?id=1155749193","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155749193?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:59","pubTimestamp":1777978765,"startTime":"0","endTime":"0","summary":"BioNTech SE (BNTX)今日盘前股价大跌5.59%，引起了市场的广泛关注。消息面上，BioNTech宣布将关闭位于德国和新加坡的多个生产基地，此举将影响多达1,860名员工。同时，公司计划将新冠疫苗的生产全面转移给合作伙伴辉瑞，德国本土将不再设立生产线。此外，BioNTech报告第一季度净亏损5.32亿欧元，较去年同期亏损有所扩大。公司表示将加大成本削减力度，预计到2029年每年可节省约5亿欧元，并计划回购价值高达10亿美元的本公司股票。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178819416","title":"BioNTech宣布2026年新冠疫苗生产将全面移交辉瑞 德国本土不再设生产线","url":"https://stock-news.laohu8.com/highlight/detail?id=1178819416","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178819416?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:45","pubTimestamp":1777977948,"startTime":"0","endTime":"0","summary":"BioNTech SE近日披露重大生产调整方案，计划于2026年内将新冠疫苗的完整生产流程转移至合作伙伴辉瑞旗下生产基地。这意味着该疫苗在德国境内的生产线将全面停止运作。\n此次战略调整标志着两家企业在疫情后期对疫苗生产布局的重新规划。作为曾经主导欧洲疫苗供应的德国生物技术公司，BioNTech将把生产重心完全转向技术研发与创新平台建设，而辉瑞将承担后续所有生产环节的全球供应链管理。\n业内观察人士指出，这一转变既反映了新冠疫苗需求常态化的市场现实，也体现出生物医药行业全球分工的深化趋势。两家企业未来将继续保持研发端的紧密合作，但生产职能的集中化将有助于优化成本结构并提升运营效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","BK4599","BK4548","SG9999013999.USD","BK4535","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0122379950.USD","LU0321505439.SGD","LU0306806265.USD","BK4551","LU1894683264.USD","IE00B19Z3B42.SGD","PFE","SG9999001176.USD","IE00BBT3K403.USD","SG9999002224.SGD","SG9999011175.SGD","SG9999003800.SGD","LU0225771236.USD","LU0058720904.USD","LU0170899867.USD","LU1023059063.AUD","LU0868494617.USD","LU0456855351.SGD","LU1066053197.SGD","LU1883839398.USD","BK4581","LU0225284248.USD","SG9999002232.USD","SG9999001176.SGD","LU0234572021.USD","BK4568","IE00B3T34201.USD","BK4592","IE000M9KFDE8.USD","LU0321505868.SGD","LU0985481810.HKD","BK4585","BK4588","IE0002270589.USD","BK4534","LU1057294990.SGD","LU0306807586.USD","BK4533","SGXZ57979304.SGD","BK4550","LU1894683348.USD","IE00B19Z3581.USD","LU1066051498.USD","BK4139","BK4007","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108621147","title":"BioNTech预计2029年全面实施成本削减措施后 每年将实现约5亿欧元经常性节约","url":"https://stock-news.laohu8.com/highlight/detail?id=1108621147","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108621147?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:45","pubTimestamp":1777977917,"startTime":"0","endTime":"0","summary":"德国生物技术公司BioNTech SE宣布，随着公司成本优化战略的全面落地，预计到2029年将实现每年约5亿欧元的经常性开支节约。\n这一重大成本削减计划将通过对研发管线、组织架构和运营效率的系统性优化来实现。公司表示，节约的资金将用于强化其在肿瘤学和传染病领域的创新药物研发。\nBioNTech强调，此次成本优化不会影响核心研发项目的推进，反而将通过资源重新配置提升研发效率。公司预计从2024年起将分阶段实施相关措施，并在2029年达成全面成效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4551","BK4588","BK4535","BK4585","BK4548","BNTX","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183652207","title":"财报前瞻｜BioNTech SE本季度营收预计减5.87%，机构观点中性偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1183652207","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183652207?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:34","pubTimestamp":1777340062,"startTime":"0","endTime":"0","summary":"BioNTech SE将于2026年05月05日盘前公布最新季度业绩，市场聚焦收入下行幅度与管线催化对情绪的拉动效应。公司当前主营由疫苗相关与合作收入构成，其中新冠肺炎疫苗为主要收入来源，贡献19.95亿欧元，占比69.53%，收入结构集中且对需求波动较敏感。上季度公司实现营收9.07亿欧元，同比下降23.75%；毛利率66.63%；归属于母公司股东的净亏损为3.05亿欧元，净利率为-33.61%；调整后每股收益为-1.25，同比下降215.74%。近期机构观点呈中性偏谨慎为主。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜BioNTech SE本季度营收预计减5.87%，机构观点中性偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121385572","title":"Trastuzumab Pamirtecan在2期子宫内膜癌队列中达到主要疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1121385572","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121385572?lang=zh_cn&edition=full","pubTime":"2026-04-13 14:07","pubTimestamp":1776060460,"startTime":"0","endTime":"0","summary":"BioNTech SE与DualityBio的抗体偶联药物Trastuzumab Pamirtecan，在治疗表达HER2的复发性子宫内膜癌患者中，展现出具有临床意义的疗效。根据公布的数据，该药物在所有HER2表达水平中均表现出显著的抗肿瘤活性，并具备可控的安全性特征。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BNTX","BK4139","BK4535","BK4585","BK4588","BK4551","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624529418","title":"辉瑞和BioNTech停止在美国的一项新冠疫苗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2624529418","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624529418?lang=zh_cn&edition=full","pubTime":"2026-04-02 10:26","pubTimestamp":1775096794,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SG9999001176.USD","LU0225771236.USD","IE000M9KFDE8.USD","LU0225284248.USD","LU0321505868.SGD","BK4581","LU0306807586.USD","IE0002270589.USD","LU0985481810.HKD","LU1894683264.USD","SG9999001176.SGD","BK4588","BK4533","IE00BLSP4452.SGD","IE00BBT3K403.USD","BK4568","BK4007","BK4592","LU0122379950.USD","LU0170899867.USD","SG9999002232.USD","SGXZ57979304.SGD","BK4534","SG9999011175.SGD","SG9999013999.USD","LU0321505439.SGD","BK4550","IE00BLSP4239.USD","LU1894683348.USD","SG9999002224.SGD","SG9999003800.SGD","LU0306806265.USD","LU0456855351.SGD","PFE","BK4599","LU0868494617.USD","LU1883839398.USD","BNTX","LU0234572021.USD","LU1066051498.USD","LU1066053197.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0289739699.SGD","BK4585","LU1057294990.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122810902","title":"辉瑞与合作伙伴BioNTech宣布：因招募缓慢将终止美国50至64岁健康成年人新冠疫苗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1122810902","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122810902?lang=zh_cn&edition=full","pubTime":"2026-04-01 23:35","pubTimestamp":1775057741,"startTime":"0","endTime":"0","summary":"辉瑞与合作伙伴BioNTech SE近日宣布，由于受试者招募进度未达预期，将终止针对美国50至64岁健康成年人群的新冠疫苗临床研究项目。两家公司透露，该年龄组志愿者的入组速度显著低于计划目标，导致研究难以按原定方案推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0122379950.USD","IE00BLSP4239.USD","SG9999011175.SGD","LU0289739699.SGD","BK4568","IE00B19Z3B42.SGD","LU1883839398.USD","BK4550","IE00BLSP4452.SGD","BK4581","BNTX","LU0306806265.USD","LU0321505439.SGD","BK4599","BK4548","SGXZ57979304.SGD","BK4534","LU0868494617.USD","LU1894683264.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","PFE","LU0170899867.USD","LU1057294990.SGD","BK4592","SG9999013999.USD","BK4007","LU0306807586.USD","IE0002270589.USD","BK4551","SG9999001176.SGD","LU0985481810.HKD","SG9999002232.USD","LU0225771236.USD","LU0225284248.USD","SG9999002224.SGD","SG9999001176.USD","IE00BBT3K403.USD","LU0234572021.USD","LU1066051498.USD","BK4533","LU1066053197.SGD","BK4535","LU0456855351.SGD","LU1894683348.USD","LU0321505868.SGD","BK4139","LU1023059063.AUD","BK4588","SG9999003800.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618940472","title":"BioNTech创始人将离职创立新的mRNA企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940472","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618940472?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:11","pubTimestamp":1773234660,"startTime":"0","endTime":"0","summary":"BioNTech （BNTX）表示，联合创始人乌古尔·萨欣和厄兹莱姆·图雷齐将离职创办一家专注于mRNA的新公司，BioNTech将持有少数股权并提供某些技术授权。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-11/doc-inhqrrth2401842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4568","BK4588","SINA","BK4548","BK4535","BNTX","BK4551","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618951995","title":"美股异动 | 2026年收入指引低于预期 BioNTech(BNTX.US)暴跌超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618951995","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618951995?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:46","pubTimestamp":1773153966,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，BioNTech盘初暴跌超20%，创4月25日以来最大跌幅，现报80.20美元。消息面上，此前该公司公布的第四季度调整后亏损以及2026年全年收入指引均低于分析师的预期。公司报告称，第四季度每股稀释后调整亏损为0.33欧元，而一年前每股盈利为1.79欧元，FactSet调查的分析师预计每股亏损为0.16欧元。对于2026年，该公司表示预计收入将在20亿欧元至23亿欧元之间，FactSet调查的分析师预计收入为27.5亿欧元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"55e023d8b9b1e3375a9483dab88b04b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4568","BK4535","BK4139","BNTX","BK4548","BK4588","BK4585","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191971117","title":"异动解读 | 创始人离职叠加业绩指引下调，BioNTech盘中暴跌21.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191971117","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191971117?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:45","pubTimestamp":1773150305,"startTime":"0","endTime":"0","summary":"BioNTech SE (BNTX) 今日盘中股价大幅下挫21.54%，引发了市场的广泛关注。消息面上，公司联合创始人兼核心领导层Ugur Sahin和Oezlem Tuereci宣布将于2026年底离开公司，以创立自己的新企业。这一关键人事变动引发了投资者对公司未来战略连续性与管理层稳定性的深度担忧，被认为是冲击股价的首要因素。与此同时，公司发布的第四季度财务报告显示营收同比下滑，净亏损扩大。更为关键的是，公司下调了2026年全年业绩指引，预计总收入为20亿至23亿欧元，远低于市场此前27.5亿欧元的预期。黯淡的财务前景与盈利挑战进一步加剧了市场的抛售情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"55e023d8b9b1e3375a9483dab88b04b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141487455","title":"美股盘前｜蔚来涨超6%，BNTX大跌16%；特朗普称有可能有条件同伊朗谈判；SpaceX倾向赴纳斯达克进行IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1141487455","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141487455?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:09","pubTimestamp":1773144598,"startTime":"0","endTime":"0","summary":"摘要：特朗普称有可能有条件同伊朗谈判SpaceX倾向赴纳斯达克进行IPO，将提前纳入纳斯达克100指数作为条件首次季度盈利！其中两位消息人士称，SpaceX将提前纳入纳斯达克100指数作为在这家科技股交易所上市的必要条件。据路透此前报道，SpaceX计划最早于今年6月进行IPO。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"55e023d8b9b1e3375a9483dab88b04b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4534","BK4505","BK4509","BK4574","BK4581",".DJI","BK4099","LU0052750758.USD","BK1588",".SPX","BK4588","BK6125","BK1119","BK4526","BK4504","BK4532",".IXIC","LU0708995583.HKD","NIO","BNTX","LU0320764599.SGD","BK4585","BK4531","BK4555"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1113795355","title":"BioNTech创始人夫妇萨欣与图雷吉将离职成立新公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1113795355","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113795355?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:02","pubTimestamp":1773140536,"startTime":"0","endTime":"0","summary":"生物技术公司BioNTech周二表示，其联合创始人Ugur Sahin和Oezlem Tuereci将于2026年底前离开这家新冠疫苗制造商，以创立他们自己的新公司。公司在一份声明中表示：“BioNTech监事会已启动高管遴选程序，以确定继任者人选，从而确保平稳过渡，并保证BioNTech战略能够持续、顺畅地执行。”BioNTech盘前跌逾14%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/c13b15b77fdb00714b0cdfb36ef3c9ad","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/c13b15b77fdb00714b0cdfb36ef3c9ad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e97184404937945405da3423e523494d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168969614","title":"BioNTech全年每股亏损4.7欧元 营收超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1168969614","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168969614?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:57","pubTimestamp":1773140253,"startTime":"0","endTime":"0","summary":"BioNTech SE公布的最新财务数据显示，其全年营收达到28.699亿欧元，显著超越市场预期。此前，机构IBES对其营收的预估值为27.37亿欧元。然而，在营收表现亮眼的同时，公司全年每股收益为负4.7欧元，表明其盈利能力面临挑战。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4568","BK4548","BK4588","BNTX","BK4535","BK4139","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180026932","title":"异动解读 | BioNTech创始夫妇宣布离职，股价盘前大跌14.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180026932","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180026932?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:52","pubTimestamp":1773139963,"startTime":"0","endTime":"0","summary":"BioNTech SE (BNTX) 今日盘前股价大幅下挫14.84%，引发了市场的高度关注。消息面上，BioNTech的联合创始人兼核心领导层Ugur Sahin和Oezlem Tuereci宣布将于2026年底离开公司，以成立自己的新公司。这一关键人事变动引发了投资者对公司未来战略连续性和管理层稳定性的担忧，被认为是导致股价急跌的主要原因。根据公司声明，BioNTech监事会已开始物色继任者，以确保平稳过渡。Sahin和Tuereci作为公司的灵魂人物，其离职决定无疑给市场带来了不确定性，并可能影响投资者对公司长期发展前景的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e97184404937945405da3423e523494d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120337490","title":"BioNTech SE四季度营收同比下滑，预计2026年总收入不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1120337490","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120337490?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:51","pubTimestamp":1773139900,"startTime":"0","endTime":"0","summary":"3月10日，BioNTech SE暴跌逾15%！预计2026年总收入为20亿至23亿欧元，不及预期。","market":"us","thumbnail":"https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1a848e5e265147d0872d15bef61ff0d3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioNTech SE四季度营收同比下滑，预计2026年总收入不及预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167701131","title":"BioNTech将于2026年3月10日公布2025年第四季度及全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1167701131","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167701131?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:50","pubTimestamp":1771933815,"startTime":"0","endTime":"0","summary":"德国美因茨，2026年2月24日——BioNTech SE将于2026年3月10日星期二发布其2025年第四季度及全年的财务业绩。同日，公司将于美国东部时间上午8:00举行电话会议和网络直播，面向投资者、财务分析师及公众讨论财务业绩并提供公司最新动态。BioNTech是一家全球性的新一代免疫疗法公司，致力于开发针对癌症及其他重大疾病的新型研究性疗法。更多信息请访问www.BioNTech.com。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4230","BK4588","BK4022","BK4585","BK4548","BK4535","BNTX","CAR","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612287922","title":"BioNTech控告Moderna侵犯新冠疫苗专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2612287922","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612287922?lang=zh_cn&edition=full","pubTime":"2026-02-20 03:26","pubTimestamp":1771529160,"startTime":"0","endTime":"0","summary":"德国生物制药公司BioNTech周四在特拉华州联邦法院起诉Moderna，指控Moderna的新冠疫苗 mNEXSPIKE侵犯了BioNTech和辉瑞公司的竞争性疫苗Comirnaty的相关专利。　　该诉讼称，Moderna公司于2025年获得美国食品药品管理局批准的下一代新冠疫苗mNEXSPIKE，侵犯了BioNTech公司在用于简化mRNA疫苗设计的技术方面的权利，该技术允许以较低剂量为患者接种。　　Moderna在2022年起诉BioNTech及其合作伙伴辉瑞公司侵犯了Comirnaty的专利权，目前诉讼仍在进行中。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-20/doc-inhnkyhw6558658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MRNX","BNTX","MRNA","MRNY"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.biontech.com","stockEarnings":[{"period":"1week","weight":0.0151},{"period":"1month","weight":0.0353},{"period":"3month","weight":0.0181},{"period":"6month","weight":-0.0174},{"period":"1year","weight":-0.1294},{"period":"ytd","weight":-0.0453}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学，尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究，开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制，利用各种生物学靶点，利用每位患者免疫系统的力量，解决每位患者潜在疾病的独特分子特征。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.014337},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.037906},{"month":3,"riseRate":0.571429,"avgChangeRate":0.057688},{"month":4,"riseRate":0.428571,"avgChangeRate":0.076942},{"month":5,"riseRate":0.571429,"avgChangeRate":0.029093},{"month":6,"riseRate":0.571429,"avgChangeRate":0.034583},{"month":7,"riseRate":1,"avgChangeRate":0.149272},{"month":8,"riseRate":0.5,"avgChangeRate":-0.051873},{"month":9,"riseRate":0.333333,"avgChangeRate":0.020492},{"month":10,"riseRate":0.666667,"avgChangeRate":0.023565},{"month":11,"riseRate":0.857143,"avgChangeRate":0.192937},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.033371}],"exchange":"NASDAQ","name":"BioNTech SE","nameEN":"BioNTech SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioNTech SE,BNTX,BioNTech SE股票,BioNTech SE股票老虎,BioNTech SE股票老虎国际,BioNTech SE行情,BioNTech SE股票行情,BioNTech SE股价,BioNTech SE股市,BioNTech SE股票价格,BioNTech SE股票交易,BioNTech SE股票购买,BioNTech SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}